CCR Inhibitors

CCR1

CCR2

CCR3

CCR4

CCR5

CCR6

CCR7

CCR8

CCR9

CCR Inhibitors, Agonists, Antagonists & Chemicals

Product Name	CCR1	CCR2	CCR3	CCR4	CCR5	CCR6	CCR7	CCR8	CCR9	Purity
Maraviroc					MIP-1α-CCR5, IC₅₀: 3.3 nM (in HEK-293 cell membrane) MIP-1β-CCR5, IC₅₀: 7.2 nM (in HEK-293 cell membrane) RANTES-CCR5, IC₅₀: 5.2 nM (in HEK-293 cell membrane)					99.88%
RS 504393		CCR2, IC₅₀: 89 nM								99.43%
BX471	MIP-1α-CCR1, Ki: 1 nM RANTES-CCR1, Ki: 2.8 nM MCP-3-CCR1, Ki: 5.5 nM									99.94%
INCB3344		hCCR2, IC₅₀: 5.1 nM mCCR2, IC₅₀: 9.5 nM								99.73%
TAK-779		MCP-1-CCR2b, IC₅₀: 27 nM (in CHO/CCR5 cells)			MIP-1α-CCR5, IC₅₀: 1 nM (in CHO/CCR5 cells) RANTES-CCR5, IC₅₀: 1.4 nM (in CHO/CCR5 cells) MIP-1β-CCR5, IC₅₀: 1 nM (in CHO/CCR5 cells)					99.73%
RS102895 hydrochloride	CCR1, IC₅₀: 17800 nM	CCR2, IC₅₀: 360 nM								99.87%
CCR6 antagonist 1						CCR6				99.55%
PF-4136309		Human CCR2, IC₅₀: 5.2 nM Mouse CCR2, IC₅₀: 13 nM Rat CCR2, IC₅₀: 17 nM								99.79%
Cenicriviroc		CCR2, IC₅₀: 5.9 nM			CCR5, IC₅₀: 0.29 nM					99.01%
Zelnecirnon				CCR4						99.84%
BX471 hydrochloride	MIP-1α-CCR1, Ki: 1 nM RANTES-CCR1, Ki: 2.8 nM MCP-3-CCR1, Ki: 5.5 nM									99.94%
CCR6 inhibitor 1						Moneky CCR6, IC₅₀: 0.45 nM Human CCR6, IC₅₀: 6 nM	Human CCR7, IC₅₀: 9400 nM			99.60%
K777				CCR4						99.77%
GW 766994			CCR3, pKi: 7.86							98.77%
C-021				CCR4						99.95%
AZD2098				CCR4						99.84%
CCR7 Ligand 1							Human CCR7, Kd: 3 nM			99.62%
AZ084								CCR8, Ki: 0.9 nM		99.65%
J-113863	CCR1, IC₅₀: 0.9 nM (Human CCR1) CCR1, IC₅₀: 5.8 nM (Mouse CCR1)		CCR3, IC₅₀: 0.58 nM (Human CCR3) CCR3, IC₅₀: 460 nM (Mouse CCR3)							≥99.0%
ZK756326 dihydrochloride								CCR8, IC₅₀: 1.8 μM (in U87 cells)		99.88%
Tivumecirnon				CCR4						99.85%
R243								CCR8		98.04%
RS102895	CCR1, IC₅₀: 17800 nM	CCR2, IC₅₀: 360 nM								99.97%
BMS-813160		CCR2, IC₅₀: 6.2 nM			CCR5, IC₅₀: 3.6 nM					99.93%
CCR2 antagonist 4 hydrochloride		CCR2b, IC₅₀: 180 nM								99.86%
Vercirnon									CCR9, IC₅₀: 10 nM	98.26%
PF-07054894						CCR6				99.12%
SB-328437			CCR3, IC₅₀: 4.5 nM							99.54%
Cenicriviroc Mesylate		CCR2, IC₅₀: 5.9 nM			CCR5, IC₅₀: 0.29 nM					99.04%
MK-0812 Succinate		CCR2								99.90%
Mogamulizumab				CCR4
BMS CCR2 22		CCR2, IC₅₀: 5.1 nM								99.87%
DAPTA					gp120_BaL/sCD4-CCR5, IC₅₀: 55 pM (in Cf2Th/synR5 cells) gp120CM_CM235/sCD4-CCR5, IC₅₀: 0.32 nM (in Cf2Th/synR5 cells)					99.85%
ML604086								CCR8		99.80%
CCR2-RA-[R]		CCR2, IC₅₀: 103 nM (in U2OS-CCR2 cells)								99.71%
LMD-009								CCR8, EC₅₀: 11-87 nM		99.35%
GSK2239633A				[¹²⁵I]-TARC-CCR4, pIC₅₀: 7.96						99.81%
INCB 3284		MCP-1-hCCR2, IC₅₀: 3.7 nM								99.30%
CCR2 antagonist 1		CCR2, Ki: 2.4 nM								98.00%
BI 639667	CCR1, IC₅₀: 1.8 nM (in Ca²⁺ flux assay)									99.47%
ALK4290			CCR3, Ki: 3.2 nM							99.79%
Ilacirnon		hCCR2, Kd: 2.3 nM (in monocytes) CCR2, IC₅₀: 3 nM (in THP-1 cells)			CCR5, IC₅₀: 7 μM (in Activated T lymphocytes)					99.87%
CCR8 antagonist 1								CCR8, Ki: 1.6 nM		99.50%
Vicriviroc maleate					CCR5, Ki: 2.5 nM					99.91%
CCR1 antagonist 9	CCR1, IC₅₀: 6.8 nM (in calcium flux assay)									99.93%
CCR2 antagonist 4		CCR2b, IC₅₀: 180 nM								99.89%
CCR8 antagonist 2								CCR8		99.71%
CKLF1-C27				CCR4						98.46%
YM022	CCR1, Ki: 63 nM	CCR2, Ki: 68 pM								99.93%
CKLF1-C19			CCR3	CCL17-CCR4						99.95%
AZD2423		CCR2								99.91%
CCR4 antagonist 4				CCR4, IC₅₀: 0.02 μM						99.72%
Vercirnon sodium									CCR9, IC₅₀: 10 nM	99.13%
TAK-220					RANTES-CCR5, IC₅₀: 3.5 nM (in CHO cells) MIP-1α-CCR5, IC₅₀: 1.4 nM (in CHO cells)					99.95%
CCX354	CCR1									99.18%
CCR4-351				CCR4						98.95%
Plozalizumab		CCR2
C-021 dihydrochloride				CCR4						99.92%
BMS-817399	CCR1, IC₅₀: 1 nM									99.83%
Aplaviroc hydrochloride					CCR5					99.93%
MK-0812		CCR2								99.75%
AZD-5672					CCR5, IC₅₀: 0.32 nM
CCR3 antagonist 1			CCR3							98.95%
Cosalane							Human CCR7 Murine CCR7			99.78%
Cosalane							Human CCR7 Murine CCR7			99.78%
CCR2 antagonist 3		CCR2								99.84%
CCR4 antagonist 3-1				[¹²⁵I]-TARC-CCR4, IC₅₀: 1.7 μM						99.94%
CCR4-351 hydrochloride				CCR4						98.37%
PF-04634817		Rat CCR2, IC₅₀: 20.8 nM			CCR5, IC₅₀: 470 nM					98.87%
Met-RANTES (human)	CCR1				CCR5
JNJ-41443532		hCCR2, IC₅₀: 37 nM mCCR2, Ki: 9.6 μM								99.65%
INCB3344 R-isomer		CCR2
Nifeviroc					CCR5					98.17%
Aplaviroc					CCR5
INCB 3284 dimesylate		MCP-1-hCCR2, IC₅₀: 3.7 nM								≥98.0%
PF-04634817 succinate		Rat CCR2, IC₅₀: 20.8 nM			CCR5, IC₅₀: 470 nM					99.50%
Maceneolignan H			CCR3
BMS-639623			CCR3, IC₅₀: 0.3 nM
CKLF1-C27 TFA				CCR4
SB-649701								CCR8, pIC₅₀: 7.7
YM-344031			CCR3
Fuscin					CCR5
CB-0821					CCR5, Ki: 0.04 nM
CCR1 antagonist 12	CCR1, IC₅₀: 3 nM
BMS-741672		CCR2, IC₅₀: 1.1 nM			CCR5, IC₅₀: 780 nM
CCR1 antagonist 10	CCR1
INCB9471					CCR5
CP-481715	CCR1, Kd: 9.2 nM
PNU-177864					CCR5
CCR5 antagonist 3					CCR5, IC₅₀: 15.90 nM
Ophiobolin C					CCR5
CCR5 antagonist 2					CCR5, IC₅₀: 8.34 nM
JNJ-27141491		hCCR2
CCR8 antagonist 3								CCR8, IC₅₀: 0.062 μM
Met-RANTES (human) (acetate)	CCR1				CCR5
CCR5 antagonist 1					CCR5

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4